Biosimilar Monoclonal Antibodies Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024

  • ID: 4702583
  • Report
  • Region: Global
  • 100 pages
  • Infinium Global Research
1 of 4

FEATURED COMPANIES

  • Allergan plc
  • Biocon
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim GmbH
  • Coherus BioSciences, Inc.
  • Genor BioPharma Co. Ltd
  • MORE
The report on global biosimilar monoclonal antibodies market provides qualitative and quantitative analysis for the period of 2016 to 2024. The report predicts the global biosimilar monoclonal antibodies market to grow with a CAGR of 55.2% over the forecast period of 2018-2024. The study on biosimilar monoclonal antibodies market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific and RoW for the period of 2016 to 2024.

The report on biosimilar monoclonal antibodies market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global biosimilar monoclonal antibodies market over the period of 2016 to 2024. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global biosimilar monoclonal antibodies market over the period of 2016 to 2024. Further, the Growth Matrix given in the report brings an insight into the investment areas that existing or new market players can consider.

Research Methodology

Primary Research

Primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached through:

1. Key Opinion Leaders associated

2. Internal and External subject matter experts

3. Professionals and participants from LinkedIn, Hoovers, Factiva and Bloggers

Primary research respondents typically include:

1. Executives working with leading companies in the market under review

2. Product/brand/marketing managers

3. CXO level executives

4. Regional/zonal/country managers

5. Vice President level executives.

Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

Secondary sources of the data typically include:

1. Company reports and publications

2. Government/institutional publications

3. Trade and associations journals

4. Databases such as WTO, OECD, World Bank, and among others.

5. Websites and publications by research agencies

Report Findings

1. Drivers
  • Rising Demand for Biosimilar Drugs Owing to their Cost Effectiveness
  • Prevalence of Chronic Diseases among Geriatric Population
2. Restraints
  • Unfavorable Government Regulations in Developed Economies
  • High Cost Associated With Manufacturing Process
3. Opportunities
  • Growing Collaboration among the Local Players
Segment Covered

The global biosimilar monoclonal antibodies market is segmented on the basis of application and drug class.

Global Biosimilar Monoclonal Antibodies Market by Application

Diagnostic Applications
  • MAbs in Biochemical Analysis
  • Pregnancy
  • Cancers
  • Hormonal disorders
  • Infectious diseases
MAbs in Diagnostic Imaging
  • Cardiovascular diseases
  • Deep vein thrombosis (DVT)
  • Atherosclerosis
  • Cancers
  • Bacterial infections
  • Therapeutic Applications
MAbs as Direct Therapeutic Agents

MAbs as Targeting Agents in Therapy
  • Protein Purification
Global Biosimilar Monoclonal Antibodies Market by Drug Class
  • Rituximab
  • Infliximab
  • Abciximab
  • Trastuzumab
  • Adalimumab
  • Bevacizumab
Company Profiles
  • Pfizer Inc.
  • Novartis AG
  • Reliance Life Sciences
  • Allergan plc
  • Coherus BioSciences, Inc.
  • Biocon
  • Boehringer Ingelheim GmbH
  • BioXpress Therapeutics SA
  • Intas Pharmaceuticals Limited
  • Genor BioPharma Co. Ltd
What does this report deliver?

1. Comprehensive analysis of global as well as regional markets of biosimilar monoclonal antibodies market.

2. Complete coverage of all the segments in biosimilar monoclonal antibodies market to analyze the trends, developments in the global market and forecast of market size up to 2024.

3. Comprehensive analysis of the companies operating in global biosimilar monoclonal antibodies market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.

4. The Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan plc
  • Biocon
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim GmbH
  • Coherus BioSciences, Inc.
  • Genor BioPharma Co. Ltd
  • MORE
1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches

2. Executive Summary
2.1. Biosimilar Monoclonal Antibodies Market Highlights
2.2. Biosimilar Monoclonal Antibodies Market Projection
2.3. Biosimilar Monoclonal Antibodies Market Regional Highlights

3. Global Biosimilar Monoclonal Antibodies Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. Growth Matrix Analysis
3.4.1. Growth Matrix Analysis by Application
3.4.2. Growth Matrix Analysis by Drug Class
3.4.3. Growth Matrix Analysis by Region
3.5. Value chain Biosimilar Monoclonal Antibodies Market

4. Biosimilar Monoclonal Antibodies Market Macro Indicator Analysis

5. Global Biosimilar Monoclonal Antibodies Market by Application
5.1. Diagnostic Applications
5.1.1 MAbs in Biochemical Analysis
5.1.1.1 Pregnancy
5.1.1.2 Cancers
5.1.1.3 Hormonal disorders
5.1.1.4 Infectious diseases
5.1.2. MAbs in Diagnostic Imaging
5.1.2.1 Cardiovascular diseases
5.1.2.2 Deep vein thrombosis (DVT)
5.1.2.3 Atherosclerosis
5.1.2.4 Cancers
5.1.2.5 Bacterial infections
5.2. Therapeutic Applications
5.2.1 MAbs as Direct Therapeutic Agents
5.2.2 MAbs as Targeting Agents in Therapy
5.3. Protein Purification

6. Global Biosimilar Monoclonal Antibodies Market by Drug Class
6.1. Rituximab
6.2. Infliximab
6.3. Abciximab
6.4. Trastuzumab
6.5. Adalimumab
6.6. Bevacizumab

7. Global Biosimilar Monoclonal Antibodies Market by Region 2018-2024
7.1. North America
7.1.1. North America Biosimilar Monoclonal Antibodies Market by Application
7.1.2. North America Biosimilar Monoclonal Antibodies Market by Drug Class
7.1.3. North America Biosimilar Monoclonal Antibodies Market by Country
7.2. Europe
7.2.1. Europe Biosimilar Monoclonal Antibodies Market by Application
7.2.2. Europe Biosimilar Monoclonal Antibodies Market by Drug Class
7.2.3. Europe Biosimilar Monoclonal Antibodies Market by Country
7.3. Asia-Pacific
7.3.1. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Application
7.3.2. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Drug Class
7.3.3. Asia-Pacific Biosimilar Monoclonal Antibodies Market by Country
7.4. RoW
7.4.1. RoW Biosimilar Monoclonal Antibodies Market by Application
7.4.2. RoW Biosimilar Monoclonal Antibodies Market by Drug Class
7.4.3. RoW Biosimilar Monoclonal Antibodies Market by Sub-region

8. Company Profiles and Competitive Landscape
8.1. Competitive Landscape in the Global Biosimilar Monoclonal Antibodies Market
8.2. Companies Profiles
8.2.1. pfizer, Inc.
8.2.1.1. Overview
8.2.1.2. Company Snapshot
8.2.1.3. Financial Snapshot
8.2.1.4. Product portfolio
8.2.1.5. Recent developments
8.2.2. Novartis Ag
8.2.2.1. Overview
8.2.2.2. Company Snapshot
8.2.2.3. Financial Snapshot
8.2.2.4. Product portfolio
8.2.2.5. Recent developments
8.2.3. Reliance Life Sciences
8.2.3.1. Overview
8.2.3.2. Company Snapshot
8.2.3.3. Financial Snapshot
8.2.3.4. Product portfolio
8.2.3.5. Recent developments
8.2.4. Allergan Plc
8.2.4.1. Overview
8.2.4.2. Company Snapshot
8.2.4.3. Financial Snapshot
8.2.4.4. Product portfolio
8.2.4.5. Recent developments
8.2.5. Coherus Biosciences, Inc.
8.2.5.1. Overview
8.2.5.2. Company Snapshot
8.2.5.3. Financial Snapshot
8.2.5.4. Product portfolio
8.2.5.5. Recent developments
8.2.6. Biocon
8.2.6.1. Overview
8.2.6.2. Company Snapshot
8.2.6.3. Financial Snapshot
8.2.6.4. Product portfolio
8.2.6.5. Recent developments
8.2.7. Boehringer Ingelheim Gmbh
8.2.7.1. Overview
8.2.7.2. Company Snapshot
8.2.7.3. Financial Snapshot
8.2.7.4. Product portfolio
8.2.7.5. Recent developments
8.2.8. Bioxpress Therapeutics Sa
8.2.8.1. Overview
8.2.8.2. Company Snapshot
8.2.8.3. Financial Snapshot
8.2.8.4. Product portfolio
8.2.8.5. Recent developments
8.2.9. Intas Pharmaceuticals Limited
8.2.9.1. Overview
8.2.9.2. Company Snapshot
8.2.9.3. Financial Snapshot
8.2.9.4. Product portfolio
8.2.9.5. Recent developments
8.2.10. Genor Biopharma Co. Ltd
8.2.10.1. Overview
8.2.10.2. Company Snapshot
8.2.10.3. Financial Snapshot
8.2.10.4. Product portfolio
8.2.10.5. Recent developments

9. Appendix
9.1. Primary research findings and questionnaire
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Pfizer Inc.
  • Novartis AG
  • Reliance Life Sciences
  • Allergan plc
  • Coherus BioSciences, Inc.
  • Biocon
  • Boehringer Ingelheim GmbH
  • BioXpress Therapeutics SA
  • Intas Pharmaceuticals Limited
  • Genor BioPharma Co. Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll